Dare Bioscience Files 8-K: Material Agreement & Equity Sales
Ticker: DARE · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1401914
| Field | Detail |
|---|---|
| Company | Dare Bioscience, INC. (DARE) |
| Form Type | 8-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 9 min |
| Key Dollar Amounts | $15.0 million, $0.0001, $5.00, $7, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Dare Bioscience inked a new deal and sold some stock, filing an 8-K.
AI Summary
On October 21, 2024, Dare Bioscience, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided financial statements and exhibits. Specific details regarding the agreement and sales were not provided in this excerpt.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and regulatory risks.
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- October 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36395 (identifier) — SEC File Number
- 20-4139823 (identifier) — I.R.S. Employer Identification No.
- 3655 Nobel Drive, Suite 2 (address) — Business and Mail Address
FAQ
What is the nature of the material definitive agreement entered into by Dare Bioscience, Inc. on October 21, 2024?
The filing indicates that Dare Bioscience, Inc. entered into a material definitive agreement on October 21, 2024, but the specific details of this agreement are not provided in the excerpt.
What type of securities were sold in the unregistered sales of equity securities by Dare Bioscience, Inc.?
The filing mentions unregistered sales of equity securities by Dare Bioscience, Inc., but the specific type of securities sold is not detailed in the provided text.
What are the key items disclosed in the 8-K filing beyond the material agreement and equity sales?
In addition to the material definitive agreement and unregistered sales of equity securities, the 8-K filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
When was Dare Bioscience, Inc. incorporated, and in which jurisdiction?
Dare Bioscience, Inc. was incorporated in Delaware, as indicated by the filing.
What is the SEC file number and IRS Employer Identification Number for Dare Bioscience, Inc.?
The SEC file number for Dare Bioscience, Inc. is 001-36395, and its IRS Employer Identification Number is 20-4139823.
Filing Stats: 2,283 words · 9 min read · ~8 pages · Grade level 14.4 · Accepted 2024-10-21 17:00:35
Key Financial Figures
- $15.0 million — incoln Park committed to purchase up to $15.0 million in shares of our common stock, $0.0001
- $0.0001 — million in shares of our common stock, $0.0001 par value per share. Under the terms
- $5.00 — price of our common stock is not below $5.00 or $7.50, respectively, on the business
- $7 — our common stock is not below $5.00 or $7.50, respectively, on the business day o
- $500,000 — single Regular Purchase may not exceed $500,000. The purchase price per share for each
- $3.59 — he Purchase Agreement equals or exceeds $3.59 per share (which represents the lower o
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex10-1.htm (EX-10.1) — 230KB
- ex10-2.htm (EX-10.2) — 103KB
- ex99-1.htm (EX-99.1) — 24KB
- 0001493152-24-041796.txt ( ) — 671KB
- dare-20241021.xsd (EX-101.SCH) — 3KB
- dare-20241021_lab.xml (EX-101.LAB) — 33KB
- dare-20241021_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: October 21, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -5-